Thomas L. Hunt

2.2k total citations
60 papers, 1.8k citations indexed

About

Thomas L. Hunt is a scholar working on Pharmacology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Thomas L. Hunt has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 11 papers in Molecular Biology and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Thomas L. Hunt's work include Antibiotics Pharmacokinetics and Efficacy (12 papers), Pneumonia and Respiratory Infections (7 papers) and Antibiotic Resistance in Bacteria (6 papers). Thomas L. Hunt is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (12 papers), Pneumonia and Respiratory Infections (7 papers) and Antibiotic Resistance in Bacteria (6 papers). Thomas L. Hunt collaborates with scholars based in United States, New Zealand and Japan. Thomas L. Hunt's co-authors include John R. Lurain, E. E. Welshman, David A. Fishman, Elizabeth A. Calhoun, Michael S. Wade, David Cella, Carl Arneson, Roger Jeffs, Kevin Laliberte and Robert Schmouder and has published in prestigious journals such as Circulation, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Thomas L. Hunt

60 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas L. Hunt United States 22 399 357 333 322 303 60 1.8k
Yuhua Zhang China 24 284 0.7× 358 1.0× 543 1.6× 267 0.8× 118 0.4× 83 1.9k
Melton B. Affrime United States 30 316 0.8× 277 0.8× 255 0.8× 339 1.1× 277 0.9× 88 2.5k
Yousri M. Barri United States 21 277 0.7× 395 1.1× 324 1.0× 218 0.7× 89 0.3× 35 1.8k
Vijay Warty United States 27 427 1.1× 1.0k 2.9× 437 1.3× 177 0.5× 152 0.5× 77 3.0k
Tim Mant United Kingdom 23 141 0.4× 349 1.0× 384 1.2× 163 0.5× 158 0.5× 55 2.2k
Shin Irie Japan 24 610 1.5× 375 1.1× 289 0.9× 132 0.4× 213 0.7× 89 1.9k
M. Godin France 22 130 0.3× 222 0.6× 258 0.8× 222 0.7× 188 0.6× 94 1.4k
Bin Zhao China 23 301 0.8× 400 1.1× 388 1.2× 189 0.6× 163 0.5× 97 1.5k
B Gawrońska-Szklarz Poland 26 352 0.9× 271 0.8× 357 1.1× 112 0.3× 175 0.6× 102 1.9k
Richard E. Mullins United States 20 212 0.5× 560 1.6× 645 1.9× 157 0.5× 145 0.5× 50 2.2k

Countries citing papers authored by Thomas L. Hunt

Since Specialization
Citations

This map shows the geographic impact of Thomas L. Hunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas L. Hunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas L. Hunt more than expected).

Fields of papers citing papers by Thomas L. Hunt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas L. Hunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas L. Hunt. The network helps show where Thomas L. Hunt may publish in the future.

Co-authorship network of co-authors of Thomas L. Hunt

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas L. Hunt. A scholar is included among the top collaborators of Thomas L. Hunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas L. Hunt. Thomas L. Hunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hunt, Thomas L., Evan Tzanis, Stephen A. Bai, et al.. (2020). The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. European Journal of Drug Metabolism and Pharmacokinetics. 46(1). 85–92. 16 indexed citations
2.
Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Clinical Therapeutics. 38(1). 39–52. 44 indexed citations
3.
Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Clinical Therapeutics. 38(1). 53–65. 45 indexed citations
4.
Hunt, Thomas L., Nachum Kaplan, & Barry Hafkin. (2015). Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects. Journal of Chemotherapy. 28(3). 164–171. 9 indexed citations
5.
6.
Keyserling, Constance, Thomas L. Hunt, Robert A. Scott, et al.. (2011). Abstract 15525: CER-001, a Synthetic HDL-Mimetic, Safely Mobilizes Cholesterol in Healthy Dyslipidemic Volunteers. Circulation. 124. 13 indexed citations
7.
Schmouder, Robert, Denise Serra, Yibin Wang, et al.. (2006). FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects. The Journal of Clinical Pharmacology. 46(8). 895–904. 94 indexed citations
8.
Shah, Ajit, Thomas L. Hunt, Susan C. Gallagher, & Michael Cullen. (2005). Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Current Medical Research and Opinion. 21(4). 595–601. 33 indexed citations
9.
Kovarik, John M., et al.. (2004). Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects. The Journal of Clinical Pharmacology. 44(5). 532–537. 76 indexed citations
10.
Wade, Michael S., et al.. (2004). Pharmacokinetics of Treprostinil Sodium Administered by 28‐Day Chronic Continuous Subcutaneous Infusion. The Journal of Clinical Pharmacology. 44(5). 503–509. 35 indexed citations
11.
Wade, Michael S., et al.. (2003). Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. The Journal of Clinical Pharmacology. 44(1). 83–88. 43 indexed citations
12.
Wade, Michael S., Thomas L. Hunt, & Allen A. Lai. (2003). Effect of Continuous Subcutaneous Treprostinil Therapy on the Pharmacodynamics and Pharmacokinetics of Warfarin. Journal of Cardiovascular Pharmacology. 41(6). 908–915. 16 indexed citations
13.
Toothaker, Roger D., et al.. (2000). Absence of pharmacokinetic interaction between orally co‐administered naproxen sodium and diphenhydramine hydrochloride. Biopharmaceutics & Drug Disposition. 21(6). 229–233. 14 indexed citations
14.
Johnson, Robert D., et al.. (1999). Pharmacokinetic interaction of sparfloxacin and digoxin. Clinical Therapeutics. 21(2). 368–379. 6 indexed citations
15.
Zannikos, Peter, et al.. (1999). Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 39(10). 1044–1052. 7 indexed citations
16.
Hunt, Thomas L., et al.. (1996). Effects on the pharmacokinetics and pharmacodynamics in the elderly of coadministering ramipril with water, apple juice, and applesauce.. Pharmaceutical Research. 13(4). 639–642. 7 indexed citations
17.
Robbins, Bruce A., et al.. (1996). Safe coadministration of terbinafine and terfenadine: A placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clinical Pharmacology & Therapeutics. 59(3). 275–283. 17 indexed citations
18.
Hunt, Thomas L., et al.. (1995). A Double‐Blind, Placebo‐Controlled, Dose‐Ranging Safety Evaluation of Single‐Dose Intravenous Dolasetron in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 35(7). 705–712. 32 indexed citations
19.
Miceli, J., et al.. (1994). The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration. Clinical Pharmacology & Therapeutics. 55(2). 142. 6 indexed citations
20.
Hainer, James W., James G. Terry, Peter J. Gillies, et al.. (1994). Effect of the acyl-CoA: cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clinical Pharmacology & Therapeutics. 56(1). 65–74. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuhua Zhang Breakdown of academic impact, for papers by Melton B. Affrime Breakdown of academic impact, for papers by Yousri M. Barri Breakdown of academic impact, for papers by Vijay Warty Breakdown of academic impact, for papers by Tim Mant Breakdown of academic impact, for papers by Shin Irie Breakdown of academic impact, for papers by M. Godin Breakdown of academic impact, for papers by Bin Zhao Breakdown of academic impact, for papers by B Gawrońska-Szklarz Breakdown of academic impact, for papers by Richard E. Mullins
Rankless by CCL
2026